[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
Comment & Response
July 2019

Vaccination for the Prevention of Group B Streptococcus Infection in Nonpregnant Adults

Author Affiliations
  • 1Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université libre de Bruxelles (ULB), Brussels, Belgium
  • 2Institute for Medical Immunology, Université libre de Bruxelles (ULB), Brussels, Belgium
  • 3Centre for Environmental Health and Occupational Health, School of Public Health, Université libre de Bruxelles (ULB), Brussels, Belgium
JAMA Intern Med. 2019;179(7):998-999. doi:10.1001/jamainternmed.2019.1590

To the Editor I read with interest the recently published Invited Commentary of Barshak regarding the increasing incidence of invasive Group B Streptococcus (GBS) infection in nonpregnant adults in the United States.1,2 The potential role of vaccination in preventing invasive GBS infection in adults with risk factors such as diabetes or obesity is discussed. The author highlights the uncertainty regarding the potential effectiveness of vaccination in the nonpregnant adult population. One of the reasons proposed by the author is the absence of serotype IV in vaccine candidates. This serotype was shown to emerge as a significant cause of invasive GBS infection in nonpregnant adults in the study by Francois Watkins and colleagues,2 but also in other studies.3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×